Accuracy of self-reported tobacco use status among hematopoietic SCT patients

Shawna L Ehlers, C. A. Bronars, Christi Ann Patten, T. Brockman, C. Hughes, P. A. Decker, James R Cerhan, William Hogan, Angela Dispenzieri, Stephen Maxted Ansell, Jon Owen Ebbert, D. Gastineau

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tobacco use is a risk factor for adverse outcomes among hematopoietic SCT (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status with serum cotinine levels among HSCT patients at the time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9%) were classified as tobacco users with serum cotinine concentrations >2 ng/mL vs 29 with self-reporting. Sensitivity and specificity of self-reporting were 65.9% and 100%, respectively. Positive and negative predictive values were 100% and 96.4%, respectively. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2% and 99.2%, respectively. Factors associated with tobacco use were male gender, single relationship status, less education and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases >50% over self-reporting. Results are discussed in the context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-reporting of any tobacco use in the year before HSCT should trigger brief advice and cessation or relapse prevention counseling.

Original languageEnglish (US)
Pages (from-to)961-965
Number of pages5
JournalBone Marrow Transplantation
Volume49
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Tobacco Use
Cotinine
Serum
Sensitivity and Specificity
Secondary Prevention
Tobacco
Medical Records
Counseling
Guidelines
Transplants
Education

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Accuracy of self-reported tobacco use status among hematopoietic SCT patients. / Ehlers, Shawna L; Bronars, C. A.; Patten, Christi Ann; Brockman, T.; Hughes, C.; Decker, P. A.; Cerhan, James R; Hogan, William; Dispenzieri, Angela; Ansell, Stephen Maxted; Ebbert, Jon Owen; Gastineau, D.

In: Bone Marrow Transplantation, Vol. 49, No. 7, 2014, p. 961-965.

Research output: Contribution to journalArticle

@article{f9c71ed1b38a4f95ae999cfce76c20c1,
title = "Accuracy of self-reported tobacco use status among hematopoietic SCT patients",
abstract = "Tobacco use is a risk factor for adverse outcomes among hematopoietic SCT (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status with serum cotinine levels among HSCT patients at the time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9{\%}) were classified as tobacco users with serum cotinine concentrations >2 ng/mL vs 29 with self-reporting. Sensitivity and specificity of self-reporting were 65.9{\%} and 100{\%}, respectively. Positive and negative predictive values were 100{\%} and 96.4{\%}, respectively. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2{\%} and 99.2{\%}, respectively. Factors associated with tobacco use were male gender, single relationship status, less education and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases >50{\%} over self-reporting. Results are discussed in the context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-reporting of any tobacco use in the year before HSCT should trigger brief advice and cessation or relapse prevention counseling.",
author = "Ehlers, {Shawna L} and Bronars, {C. A.} and Patten, {Christi Ann} and T. Brockman and C. Hughes and Decker, {P. A.} and Cerhan, {James R} and William Hogan and Angela Dispenzieri and Ansell, {Stephen Maxted} and Ebbert, {Jon Owen} and D. Gastineau",
year = "2014",
doi = "10.1038/bmt.2014.70",
language = "English (US)",
volume = "49",
pages = "961--965",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Accuracy of self-reported tobacco use status among hematopoietic SCT patients

AU - Ehlers, Shawna L

AU - Bronars, C. A.

AU - Patten, Christi Ann

AU - Brockman, T.

AU - Hughes, C.

AU - Decker, P. A.

AU - Cerhan, James R

AU - Hogan, William

AU - Dispenzieri, Angela

AU - Ansell, Stephen Maxted

AU - Ebbert, Jon Owen

AU - Gastineau, D.

PY - 2014

Y1 - 2014

N2 - Tobacco use is a risk factor for adverse outcomes among hematopoietic SCT (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status with serum cotinine levels among HSCT patients at the time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9%) were classified as tobacco users with serum cotinine concentrations >2 ng/mL vs 29 with self-reporting. Sensitivity and specificity of self-reporting were 65.9% and 100%, respectively. Positive and negative predictive values were 100% and 96.4%, respectively. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2% and 99.2%, respectively. Factors associated with tobacco use were male gender, single relationship status, less education and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases >50% over self-reporting. Results are discussed in the context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-reporting of any tobacco use in the year before HSCT should trigger brief advice and cessation or relapse prevention counseling.

AB - Tobacco use is a risk factor for adverse outcomes among hematopoietic SCT (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status with serum cotinine levels among HSCT patients at the time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9%) were classified as tobacco users with serum cotinine concentrations >2 ng/mL vs 29 with self-reporting. Sensitivity and specificity of self-reporting were 65.9% and 100%, respectively. Positive and negative predictive values were 100% and 96.4%, respectively. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2% and 99.2%, respectively. Factors associated with tobacco use were male gender, single relationship status, less education and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases >50% over self-reporting. Results are discussed in the context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-reporting of any tobacco use in the year before HSCT should trigger brief advice and cessation or relapse prevention counseling.

UR - http://www.scopus.com/inward/record.url?scp=84903881655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903881655&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.70

DO - 10.1038/bmt.2014.70

M3 - Article

C2 - 24732958

AN - SCOPUS:84903881655

VL - 49

SP - 961

EP - 965

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -